ANNEXA-I: Andexanet Alfa Shows Efficacy, Safety for Factor Xa Reversal in Acute ICH
The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.
Stuart Connolly World Stroke Congress A National Institutes Of Health Stroke Scale National Institutes Health Stroke Scale Intracerebral Hemorrhage
Source: ajmc.com